Conclusion: Everolimus can delay the progression of diabetic nephropathy.
结论:依维莫司能够延缓糖尿病肾病的进展。
Severe diarrhea occurred at a higher frequency in the combination group than in the everolimus group.
严重的腹泻在联合用药组的发生率高于依维莫司组。
Because of these safety concerns, a risk evaluation and mitigation strategy has been implemented to educate patients and clinicians regarding the safe use and risks of everolimus.
基于这些安全性的考虑,研究者们正在进行一些危险评估和缓解策略,从而对患者和临床医生进行依维莫司安全使用和危险因素的相关教育。
应用推荐